Ulcerative Colitis Market Report and Forecast 2025-2034
Description
The ulcerative colitis market was valued at USD 7.49 Billion in 2024 driven by the increasing demand for advanced biologics and immunomodulators across the 8 major markets. It is expected to grow at a CAGR of 3.75% during the forecast period of 2025-2034 and attain a market value of USD 10.82 Billion by 2034.
Ulcerative Colitis Market Overview
The market is expanding primarily due to the rising number of people suffering from this chronic inflammatory bowel disease, which affects millions globally. A key driver for this expansion is the rising need for sophisticated biologics and immunomodulators. Additionally, innovative oral therapies that provide corticosteroid-free remission are gaining traction. Trends such as regulatory approvals for new treatments and strategic mergers within the industry, signal a promising expansion of the market. These developments reflect a collective effort to enhance treatment options, ultimately striving to improve the quality of life for patients suffering from ulcerative colitis globally.
Ulcerative Colitis Market Growth Drivers
Rising Prevalence of Ulcerative Colitis Drives Market Growth
The escalating incidence of ulcerative colitis has become a pivotal factor influencing the market growth. In 2023, the global prevalence was reported at approximately 5 million cases, indicating a significant increase in incidence rates across various regions. This is fostering demand for advanced treatment options, accelerating the development and market adoption of biologics and immunomodulators to address this growing healthcare need.
Ulcerative Colitis Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Rise in Strategic Mergers and Acquisitions to Affect the Market
Several market players are stepping forward to enhance their ulcerative colitis care portfolio propelled by the surge in strategic mergers and acquisitions. For instance, in June 2023, Merck & Co. completed an agreement to purchase Prometheus Biosciences for approximately USD 10.8 billion. This acquisition allows Prometheus Biosciences to fully harness the potential of PRA023, an advanced candidate in late-stage development designed to address conditions such as ulcerative colitis, Crohn's disease, and various autoimmune disorders. Such strategic mergers and acquisitions are likely to enhance innovation and competitive dynamics within the market.
Surge in Regulatory Approvals to Boost Ulcerative Colitis Market Value
The surge in regulatory approvals is significantly impacting the market dynamics positively. For, instance in December 2024, Celltrion received FDA approval for STEQEYMA (ustekinumab-stba), a biosimilar to STELARA, for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in both adults and pediatric patients. The approval, based on a phase III study demonstrating similar safety and efficacy to the reference product, marks a strategic expansion of Celltrion's immunology portfolio, thus supporting overall market growth by increasing treatment options and accessibility.
Advancements in Clinical Trials to Meet Rising Ulcerative Colitis Market Demand
Advancements in clinical trials are significantly driving innovation within the market, representing a pivotal shift towards more effective therapeutic solutions. For instance, in December 2024, Accropeutics Inc. received FDA clearance for its IND application for AC-101, a RIPK2 inhibitor, which enabled pivotal Phase II trials to evaluate its safety and efficacy in treating moderate-to-severe ulcerative colitis. This proactive approach, alongside ongoing studies in China, underscores the industry's commitment to addressing unmet medical needs and enhancing patient outcomes, thereby supporting growth and investment in the ulcerative colitis market.
Growing Awareness Campaigns to Boost Ulcerative Colitis Market Size
The increase in awareness campaigns is significantly contributing to the market expansion. These initiatives are driving public knowledge about the symptoms of ulcerative colitis, such as stomach pain, and fatigue, which is leading to earlier diagnoses and better treatment outcomes. For instance, in March 2023, the Scottish Government launched a comprehensive campaign aimed at raising awareness of Chron’s disease and ulcerative colitis. The campaign, supported by research from Crohn’s and Colitis UK, encouraged individuals to recognize symptoms early and seek medical advice. Thus, it directly supported the demand for innovative treatment solutions in the market. This rise in public awareness is set to fuel the market’s growth by encouraging more individuals to seek diagnosis and care for ulcerative colitis.
Ulcerative Colitis Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Based on the Route of Administration Oral Administration holds a Substantial Market Growth
Based on the route of administration, the market is divided into oral and injectables. Among these, the oral route is expected to dominate the market due to its convenience, ease of use, and patient preference for non-invasive treatments. Innovative oral medications, such as Balsalazide, and Mesalamine, with their potential to deliver effective, corticosteroid-free remission drive the growth of this segment. This segment is poised for significant expansion during the forecast period, largely due to increasing awareness and demand for patient-friendly treatment options.
Ulcerative Colitis Market Analysis by Region
Based on region, the market report covers the United States, United Kingdom, Germany, France, Italy, Spain, Japan and India. Among these, the United States is projected to dominate the market due to high prevalence rates, advanced healthcare infrastructure, and significant investment in research and development.
Japan will also hold a significant market share due to the presence of key players. For instance, in 2023, Takeda received the approval to manufacture and market Entyvio® subcutaneous injection in Japan, specifically for the maintenance treatment of moderate to severe ulcerative colitis. This approval represents a significant step forward for patients in Japan who are seeking effective management options for their condition.
Leading Players in the Ulcerative Colitis Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Takeda Pharmaceutical Company Limited
Established in 1781, Takeda Pharmaceutical is headquartered in Tokyo, Japan. The company has developed Entyvio (vedolizumab), a monoclonal antibody specifically targeting ulcerative colitis and Crohn’s disease. This drug has become a cornerstone therapy for moderate to severe cases of ulcerative colitis, providing patients with improved symptom control and remission rates.
Pfizer Inc.
Founded in 1849, Pfizer Inc., headquartered in New York, USA, is a global leader in healthcare innovation. For ulcerative colitis, Pfizer developed Xeljanz (tofacitinib), an oral Janus kinase (JAK) inhibitor approved for moderate to severe cases. This treatment offers patients a corticosteroid-free option for managing inflammation and achieving remission.
Eli Lilly and Company
Established in 1876, Eli Lilly is headquartered in Indianapolis, USA. The company is focusing on innovative therapies and is advancing Mirikizumab, an IL-23p19 inhibitor designed for treating moderate to severe ulcerative colitis. The therapy targets inflammation pathways, aiming to improve symptom control and long-term outcomes for patients.
Novartis AG
Founded in 1996, Novartis AG is based in Basel, Switzerland. Although primarily focused on broader immunology. Novartis is advancing therapies like Zortress (everolimus), which addresses inflammation in various conditions, including ulcerative colitis. Its contributions highlight the company’s commitment to innovation in treating inflammatory bowel diseases.
Other companies include AbbVie Inc., Bausch Health Companies Inc., Johnson & Johnson, Merck & Co., and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in the Ulcerative Colitis Market
Ulcerative Colitis Market Overview
The market is expanding primarily due to the rising number of people suffering from this chronic inflammatory bowel disease, which affects millions globally. A key driver for this expansion is the rising need for sophisticated biologics and immunomodulators. Additionally, innovative oral therapies that provide corticosteroid-free remission are gaining traction. Trends such as regulatory approvals for new treatments and strategic mergers within the industry, signal a promising expansion of the market. These developments reflect a collective effort to enhance treatment options, ultimately striving to improve the quality of life for patients suffering from ulcerative colitis globally.
Ulcerative Colitis Market Growth Drivers
Rising Prevalence of Ulcerative Colitis Drives Market Growth
The escalating incidence of ulcerative colitis has become a pivotal factor influencing the market growth. In 2023, the global prevalence was reported at approximately 5 million cases, indicating a significant increase in incidence rates across various regions. This is fostering demand for advanced treatment options, accelerating the development and market adoption of biologics and immunomodulators to address this growing healthcare need.
Ulcerative Colitis Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Rise in Strategic Mergers and Acquisitions to Affect the Market
Several market players are stepping forward to enhance their ulcerative colitis care portfolio propelled by the surge in strategic mergers and acquisitions. For instance, in June 2023, Merck & Co. completed an agreement to purchase Prometheus Biosciences for approximately USD 10.8 billion. This acquisition allows Prometheus Biosciences to fully harness the potential of PRA023, an advanced candidate in late-stage development designed to address conditions such as ulcerative colitis, Crohn's disease, and various autoimmune disorders. Such strategic mergers and acquisitions are likely to enhance innovation and competitive dynamics within the market.
Surge in Regulatory Approvals to Boost Ulcerative Colitis Market Value
The surge in regulatory approvals is significantly impacting the market dynamics positively. For, instance in December 2024, Celltrion received FDA approval for STEQEYMA (ustekinumab-stba), a biosimilar to STELARA, for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in both adults and pediatric patients. The approval, based on a phase III study demonstrating similar safety and efficacy to the reference product, marks a strategic expansion of Celltrion's immunology portfolio, thus supporting overall market growth by increasing treatment options and accessibility.
Advancements in Clinical Trials to Meet Rising Ulcerative Colitis Market Demand
Advancements in clinical trials are significantly driving innovation within the market, representing a pivotal shift towards more effective therapeutic solutions. For instance, in December 2024, Accropeutics Inc. received FDA clearance for its IND application for AC-101, a RIPK2 inhibitor, which enabled pivotal Phase II trials to evaluate its safety and efficacy in treating moderate-to-severe ulcerative colitis. This proactive approach, alongside ongoing studies in China, underscores the industry's commitment to addressing unmet medical needs and enhancing patient outcomes, thereby supporting growth and investment in the ulcerative colitis market.
Growing Awareness Campaigns to Boost Ulcerative Colitis Market Size
The increase in awareness campaigns is significantly contributing to the market expansion. These initiatives are driving public knowledge about the symptoms of ulcerative colitis, such as stomach pain, and fatigue, which is leading to earlier diagnoses and better treatment outcomes. For instance, in March 2023, the Scottish Government launched a comprehensive campaign aimed at raising awareness of Chron’s disease and ulcerative colitis. The campaign, supported by research from Crohn’s and Colitis UK, encouraged individuals to recognize symptoms early and seek medical advice. Thus, it directly supported the demand for innovative treatment solutions in the market. This rise in public awareness is set to fuel the market’s growth by encouraging more individuals to seek diagnosis and care for ulcerative colitis.
Ulcerative Colitis Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
- Anti-Inflammatory Drugs
- Amino salicylates
- Corticosteroids
- Anti-TNF Biologics
- Immuno-suppressants
- Calcineurin Inhibitors
- Others
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- Oral
- Injectable
- Biologics
- Small Molecules
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Based on the Route of Administration Oral Administration holds a Substantial Market Growth
Based on the route of administration, the market is divided into oral and injectables. Among these, the oral route is expected to dominate the market due to its convenience, ease of use, and patient preference for non-invasive treatments. Innovative oral medications, such as Balsalazide, and Mesalamine, with their potential to deliver effective, corticosteroid-free remission drive the growth of this segment. This segment is poised for significant expansion during the forecast period, largely due to increasing awareness and demand for patient-friendly treatment options.
Ulcerative Colitis Market Analysis by Region
Based on region, the market report covers the United States, United Kingdom, Germany, France, Italy, Spain, Japan and India. Among these, the United States is projected to dominate the market due to high prevalence rates, advanced healthcare infrastructure, and significant investment in research and development.
Japan will also hold a significant market share due to the presence of key players. For instance, in 2023, Takeda received the approval to manufacture and market Entyvio® subcutaneous injection in Japan, specifically for the maintenance treatment of moderate to severe ulcerative colitis. This approval represents a significant step forward for patients in Japan who are seeking effective management options for their condition.
Leading Players in the Ulcerative Colitis Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Takeda Pharmaceutical Company Limited
Established in 1781, Takeda Pharmaceutical is headquartered in Tokyo, Japan. The company has developed Entyvio (vedolizumab), a monoclonal antibody specifically targeting ulcerative colitis and Crohn’s disease. This drug has become a cornerstone therapy for moderate to severe cases of ulcerative colitis, providing patients with improved symptom control and remission rates.
Pfizer Inc.
Founded in 1849, Pfizer Inc., headquartered in New York, USA, is a global leader in healthcare innovation. For ulcerative colitis, Pfizer developed Xeljanz (tofacitinib), an oral Janus kinase (JAK) inhibitor approved for moderate to severe cases. This treatment offers patients a corticosteroid-free option for managing inflammation and achieving remission.
Eli Lilly and Company
Established in 1876, Eli Lilly is headquartered in Indianapolis, USA. The company is focusing on innovative therapies and is advancing Mirikizumab, an IL-23p19 inhibitor designed for treating moderate to severe ulcerative colitis. The therapy targets inflammation pathways, aiming to improve symptom control and long-term outcomes for patients.
Novartis AG
Founded in 1996, Novartis AG is based in Basel, Switzerland. Although primarily focused on broader immunology. Novartis is advancing therapies like Zortress (everolimus), which addresses inflammation in various conditions, including ulcerative colitis. Its contributions highlight the company’s commitment to innovation in treating inflammatory bowel diseases.
Other companies include AbbVie Inc., Bausch Health Companies Inc., Johnson & Johnson, Merck & Co., and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in the Ulcerative Colitis Market
- What was the ulcerative colitis market value in 2024?
- What is the ulcerative colitis market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the drug type?
- What is the market breakup based on the disease type?
- What is the market segmentation based on the route of administration?
- What is the market breakup based on the molecule type?
- What are the major factors aiding the ulcerative colitis market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major ulcerative colitis market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the ulcerative colitis market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Ulcerative Colitis Market Overview – 8 Major Markets
- 3.1 Ulcerative Colitis Market Historical Value (2018-2024)
- 3.2 Ulcerative Colitis Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Ulcerative Colitis Market: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Ulcerative Colitis Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 Germany
- 7.2.4 France
- 7.2.5 Italy
- 7.2.6 Spain
- 7.2.7 Japan
- 7.2.8 India
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 Germany
- 7.3.4 France
- 7.3.5 Italy
- 7.3.6 Spain
- 7.3.7 Japan
- 7.3.8 India
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 Italy
- 7.4.6 Spain
- 7.4.7 Japan
- 7.4.8 India
- 8 Ulcerative Colitis Market Landscape – 8 Major Markets
- 8.1 Ulcerative Colitis Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Ulcerative Colitis Market: Product Landscape
- 8.2.1 Analysis By Drug Type
- 8.2.2 Analysis By Disease Type
- 8.2.3 Analysis By Route of Administration
- 9 Clinical Trials and Pipeline Analysis
- 9.1 Analysis by Trial Registration Year
- 9.2 Analysis by Trial Status
- 9.3 Analysis by Trial Phase
- 9.4 Analysis by Therapeutic Area
- 9.5 Analysis by Geography
- 9.6 Drug Pipeline Analysis
- 10 Ulcerative Colitis Market Challenges and Unmet Needs
- 10.1 Treatment Pathway Challenges
- 10.2 Compliance and Drop-Out Analysis
- 10.3 Awareness and Prevention Gaps
- 11 Cost of Treatment
- 12 Ulcerative Colitis Market Dynamics
- 12.1 Market Drivers and Constraints
- 12.2 SWOT Analysis
- 12.2.1 Strengths
- 12.2.2 Weaknesses
- 12.2.3 Opportunities
- 12.2.4 Threats
- 12.3 PESTEL Analysis
- 12.3.1 Political
- 12.3.2 Economic
- 12.3.3 Social
- 12.3.4 Technological
- 12.3.5 Legal
- 12.3.6 Environment
- 12.4 Porter’s Five Forces Model
- 12.4.1 Bargaining Power of Suppliers
- 12.4.2 Bargaining Power of Buyers
- 12.4.3 Threat of New Entrants
- 12.4.4 Threat of Substitutes
- 12.4.5 Degree of Rivalry
- 12.5 Key Demand Indicators
- 12.6 Key Price Indicators
- 12.7 Industry Events, Initiatives, and Trends
- 12.8 Value Chain Analysis
- 13 Ulcerative Colitis Market Segmentation (218-2034)
- 13.1 Ulcerative Colitis Market (2018-2034) by Drug Type
- 13.1.1 Market Overview
- 13.1.2 Anti-Inflammatory Drugs
- 13.1.2.1 Amino salicylates
- 13.1.2.2 Corticosteroids
- 13.1.3 Anti-TNF biologics
- 13.1.4 Immuno-suppressants
- 13.1.5 Calcineurin Inhibitors
- 13.1.6 Others
- 13.2 Ulcerative Colitis Market (2018-2034) by Disease Type
- 13.2.1 Market Overview
- 13.2.2 Ulcerative Proctitis
- 13.2.3 Proctosigmoiditis
- 13.2.4 Left-sided Colitis
- 13.2.5 Pancolitis or Universal Colitis
- 13.2.6 Fulminant Colitis
- 13.3 Ulcerative Colitis Market (2018-2034) by Route of Administration
- 13.3.1 Market Overview
- 13.3.2 Oral
- 13.3.3 Injectable
- 13.4 Ulcerative Colitis Market (2018-2034) by Molecule Type
- 13.4.1 Market Overview
- 13.4.2 Biologics
- 13.4.3 Small Molecule
- 13.5 Ulcerative Colitis Market (2018-2034) by Region
- 13.5.1 Market Overview
- 13.5.2 United States
- 13.5.3 United Kingdom
- 13.5.4 Germany
- 13.5.5 France
- 13.5.6 Italy
- 13.5.7 Spain
- 13.5.8 Japan
- 13.5.9 India
- 14 United States Ulcerative Colitis Market Segmentation (218-2034)
- 14.1 United States Ulcerative Colitis Market (2018-2034) by Drug Type
- 14.1.1 Market Overview
- 14.1.2 Anti-Inflammatory Drugs
- 14.1.2.1 Amino salicylates
- 14.1.2.2 Corticosteroids
- 14.1.3 Anti-TNF biologics
- 14.1.4 Immuno-suppressants
- 14.1.5 Calcineurin Inhibitors
- 14.1.6 Others
- 14.2 United States Ulcerative Colitis Market (2018-2034) by Disease Type
- 14.2.1 Market Overview
- 14.2.2 Ulcerative Proctitis
- 14.2.3 Proctosigmoiditis
- 14.2.4 Left-sided Colitis
- 14.2.5 Pancolitis or Universal Colitis
- 14.2.6 Fulminant Colitis
- 14.3 United States Ulcerative Colitis Market (2018-2034) by Route of Administration
- 14.3.1 Market Overview
- 14.3.2 Oral
- 14.3.3 Injectable
- 14.4 United States Ulcerative Colitis Market (2018-2034) by Molecule Type
- 14.4.1 Market Overview
- 14.4.2 Biologics
- 14.4.3 Small Molecule
- 15 United Kingdom Ulcerative Colitis Market Segmentation (218-2034)
- 15.1 United Kingdom Ulcerative Colitis Market (2018-2034) by Drug Type
- 15.1.1 Market Overview
- 15.1.2 Anti-Inflammatory Drugs
- 15.1.2.1 Amino salicylates
- 15.1.2.2 Corticosteroids
- 15.1.3 Anti-TNF biologics
- 15.1.4 Immuno-suppressants
- 15.1.5 Calcineurin Inhibitors
- 15.1.6 Others
- 15.2 United Kingdom Ulcerative Colitis Market (2018-2034) by Disease Type
- 15.2.1 Market Overview
- 15.2.2 Ulcerative Proctitis
- 15.2.3 Proctosigmoiditis
- 15.2.4 Left-sided Colitis
- 15.2.5 Pancolitis or Universal Colitis
- 15.2.6 Fulminant Colitis
- 15.3 United Kingdom Ulcerative Colitis Market (2018-2034) by Route of Administration
- 15.3.1 Market Overview
- 15.3.2 Oral
- 15.3.3 Injectable
- 15.4 United Kingdom Ulcerative Colitis Market (2018-2034) by Molecule Type
- 15.4.1 Market Overview
- 15.4.2 Biologics
- 15.4.3 Small Molecule
- 16 Germany Ulcerative Colitis Market Segmentation (218-2034)
- 16.1 Germany Ulcerative Colitis Market (2018-2034) by Drug Type
- 16.1.1 Market Overview
- 16.1.2 Anti-Inflammatory Drugs
- 16.1.2.1 Amino salicylates
- 16.1.2.2 Corticosteroids
- 16.1.3 Anti-TNF biologics
- 16.1.4 Immuno-suppressants
- 16.1.5 Calcineurin Inhibitors
- 16.1.6 Others
- 16.2 Germany Ulcerative Colitis Market (2018-2034) by Disease Type
- 16.2.1 Market Overview
- 16.2.2 Ulcerative Proctitis
- 16.2.3 Proctosigmoiditis
- 16.2.4 Left-sided Colitis
- 16.2.5 Pancolitis or Universal Colitis
- 16.2.6 Fulminant Colitis
- 16.3 Germany Ulcerative Colitis Market (2018-2034) by Route of Administration
- 16.3.1 Market Overview
- 16.3.2 Oral
- 16.3.3 Injectable
- 16.4 Germany Ulcerative Colitis Market (2018-2034) by Molecule Type
- 16.4.1 Market Overview
- 16.4.2 Biologics
- 16.4.3 Small Molecule
- 17 France Ulcerative Colitis Market Segmentation (218-2034)
- 17.1 France Ulcerative Colitis Market (2018-2034) by Drug Type
- 17.1.1 Market Overview
- 17.1.2 Anti-Inflammatory Drugs
- 17.1.2.1 Amino salicylates
- 17.1.2.2 Corticosteroids
- 17.1.3 Anti-TNF biologics
- 17.1.4 Immuno-suppressants
- 17.1.5 Calcineurin Inhibitors
- 17.1.6 Others
- 17.2 France Ulcerative Colitis Market (2018-2034) by Disease Type
- 17.2.1 Market Overview
- 17.2.2 Ulcerative Proctitis
- 17.2.3 Proctosigmoiditis
- 17.2.4 Left-sided Colitis
- 17.2.5 Pancolitis or Universal Colitis
- 17.2.6 Fulminant Colitis
- 17.3 France Ulcerative Colitis Market (2018-2034) by Route of Administration
- 17.3.1 Market Overview
- 17.3.2 Oral
- 17.3.3 Injectable
- 17.4 France Ulcerative Colitis Market (2018-2034) by Molecule Type
- 17.4.1 Market Overview
- 17.4.2 Biologics
- 17.4.3 Small Molecule
- 18 Italy Ulcerative Colitis Market Segmentation (218-2034)
- 18.1 Italy Ulcerative Colitis Market (2018-2034) by Drug Type
- 18.1.1 Market Overview
- 18.1.2 Anti-Inflammatory Drugs
- 18.1.2.1 Amino salicylates
- 18.1.2.2 Corticosteroids
- 18.1.3 Anti-TNF biologics
- 18.1.4 Immuno-suppressants
- 18.1.5 Calcineurin Inhibitors
- 18.1.6 Others
- 18.2 Italy Ulcerative Colitis Market (2018-2034) by Disease Type
- 18.2.1 Market Overview
- 18.2.2 Ulcerative Proctitis
- 18.2.3 Proctosigmoiditis
- 18.2.4 Left-sided Colitis
- 18.2.5 Pancolitis or Universal Colitis
- 18.2.6 Fulminant Colitis
- 18.3 Italy Ulcerative Colitis Market (2018-2034) by Route of Administration
- 18.3.1 Market Overview
- 18.3.2 Oral
- 18.3.3 Injectable
- 18.4 Italy Ulcerative Colitis Market (2018-2034) by Molecule Type
- 18.4.1 Market Overview
- 18.4.2 Biologics
- 18.4.3 Small Molecule
- 19 Spain Ulcerative Colitis Market Segmentation (218-2034)
- 19.1 Spain Ulcerative Colitis Market (2018-2034) by Drug Type
- 19.1.1 Market Overview
- 19.1.2 Anti-Inflammatory Drugs
- 19.1.2.1 Amino salicylates
- 19.1.2.2 Corticosteroids
- 19.1.3 Anti-TNF biologics
- 19.1.4 Immuno-suppressants
- 19.1.5 Calcineurin Inhibitors
- 19.1.6 Others
- 19.2 Spain Ulcerative Colitis Market (2018-2034) by Disease Type
- 19.2.1 Market Overview
- 19.2.2 Ulcerative Proctitis
- 19.2.3 Proctosigmoiditis
- 19.2.4 Left-sided Colitis
- 19.2.5 Pancolitis or Universal Colitis
- 19.2.6 Fulminant Colitis
- 19.3 Spain Ulcerative Colitis Market (2018-2034) by Route of Administration
- 19.3.1 Market Overview
- 19.3.2 Oral
- 19.3.3 Injectable
- 19.4 Spain Ulcerative Colitis Market (2018-2034) by Molecule Type
- 19.4.1 Market Overview
- 19.4.2 Biologics
- 19.4.3 Small Molecule
- 20 Japan Ulcerative Colitis Market Segmentation (218-2034)
- 20.1 Japan Ulcerative Colitis Market (2018-2034) by Drug Type
- 20.1.1 Market Overview
- 20.1.2 Anti-Inflammatory Drugs
- 20.1.2.1 Amino salicylates
- 20.1.2.2 Corticosteroids
- 20.1.3 Anti-TNF biologics
- 20.1.4 Immuno-suppressants
- 20.1.5 Calcineurin Inhibitors
- 20.1.6 Others
- 20.2 Japan Ulcerative Colitis Market (2018-2034) by Disease Type
- 20.2.1 Market Overview
- 20.2.2 Ulcerative Proctitis
- 20.2.3 Proctosigmoiditis
- 20.2.4 Left-sided Colitis
- 20.2.5 Pancolitis or Universal Colitis
- 20.2.6 Fulminant Colitis
- 20.3 Japan Ulcerative Colitis Market (2018-2034) by Route of Administration
- 20.3.1 Market Overview
- 20.3.2 Oral
- 20.3.3 Injectable
- 20.4 Japan Ulcerative Colitis Market (2018-2034) by Molecule Type
- 20.4.1 Market Overview
- 20.4.2 Biologics
- 20.4.3 Small Molecule
- 21 India Ulcerative Colitis Market Segmentation (218-2034)
- 21.1 India Ulcerative Colitis Market (2018-2034) by Drug Type
- 21.1.1 Market Overview
- 21.1.2 Anti-Inflammatory Drugs
- 21.1.2.1 Amino salicylates
- 21.1.2.2 Corticosteroids
- 21.1.3 Anti-TNF biologics
- 21.1.4 Immuno-suppressants
- 21.1.5 Calcineurin Inhibitors
- 21.1.6 Others
- 21.2 India Ulcerative Colitis Market (2018-2034) by Disease Type
- 21.2.1 Market Overview
- 21.2.2 Ulcerative Proctitis
- 21.2.3 Proctosigmoiditis
- 21.2.4 Left-sided Colitis
- 21.2.5 Pancolitis or Universal Colitis
- 21.2.6 Fulminant Colitis
- 21.3 India Ulcerative Colitis Market (2018-2034) by Route of Administration
- 21.3.1 Market Overview
- 21.3.2 Oral
- 21.3.3 Injectable
- 21.4 India Ulcerative Colitis Market (2018-2034) by Molecule Type
- 21.4.1 Market Overview
- 21.4.2 Biologics
- 21.4.3 Small Molecule
- 22 Regulatory Framework
- 22.1 Regulatory Overview
- 22.2 US FDA
- 22.3 EU EMA
- 22.4 Japan PMDA
- 22.5 India CDSCO
- 22.6 Others
- 23 Patent Analysis
- 23.1 Analysis by Type of Patent
- 23.2 Analysis by Publication Year
- 23.3 Analysis by Issuing Authority
- 23.4 Analysis by Patent Age
- 23.5 Analysis by CPC Analysis
- 23.6 Analysis by Patent Valuation
- 24 Grants Analysis
- 24.1 Analysis by Year
- 24.2 Analysis by Amount Awarded
- 24.3 Analysis by Issuing Authority
- 24.4 Analysis by Grant Application
- 24.5 Analysis by Funding Institute
- 24.6 Analysis by NIH Departments
- 24.7 Analysis by Recipient Organization
- 25 Funding and Investment Analysis
- 25.1 Analysis by Funding Instances
- 25.2 Analysis by Drug Class of Funding
- 25.3 Analysis by Funding Amount
- 25.4 Analysis by Leading Players
- 25.5 Analysis by Leading Investors
- 25.6 Analysis by Geography
- 26 Strategic Initiatives
- 26.1 Analysis by Partnership Instances
- 26.2 Analysis by Drug Class of Partnership
- 26.3 Analysis by Leading Players
- 26.4 Analysis by Geography
- 27 Supplier Landscape
- 27.1 Market Share Analysis, By Region (Top 5 Companies)
- 27.2 AbbVie Inc.
- 27.2.1 Financial Analysis
- 27.2.2 Product Portfolio
- 27.2.3 Demographic Reach and Achievements
- 27.2.4 Company News and Development
- 27.2.5 Certifications
- 27.3 Bausch Health Companies Inc.
- 27.3.1 Financial Analysis
- 27.3.2 Product Portfolio
- 27.3.3 Demographic Reach and Achievements
- 27.3.4 Company News and Development
- 27.3.5 Certifications
- 27.4 Johnson & Johnson
- 27.4.1 Financial Analysis
- 27.4.2 Product Portfolio
- 27.4.3 Demographic Reach and Achievements
- 27.4.4 Company News and Development
- 27.4.5 Certifications
- 27.5 Merck & Co.
- 27.5.1 Financial Analysis
- 27.5.2 Product Portfolio
- 27.5.3 Demographic Reach and Achievements
- 27.5.4 Company News and Development
- 27.5.5 Certifications
- 27.6 Takeda Pharmaceutical Company Limited
- 27.6.1 Financial Analysis
- 27.6.2 Product Portfolio
- 27.6.3 Demographic Reach and Achievements
- 27.6.4 Company News and Development
- 27.6.5 Certifications
- 27.7 Teva Pharmaceutical Industries Ltd
- 27.7.1 Financial Analysis
- 27.7.2 Product Portfolio
- 27.7.3 Demographic Reach and Achievements
- 27.7.4 Company News and Development
- 27.7.5 Certifications
- 27.8 Pfizer Inc.
- 27.8.1 Financial Analysis
- 27.8.2 Product Portfolio
- 27.8.3 Demographic Reach and Achievements
- 27.8.4 Company News and Development
- 27.8.5 Certifications
- 27.9 Eli Lilly and Company
- 27.9.1 Financial Analysis
- 27.9.2 Product Portfolio
- 27.9.3 Demographic Reach and Achievements
- 27.9.4 Company News and Development
- 27.9.5 Certifications
- 27.10 Novartis AG
- 27.10.1 Financial Analysis
- 27.10.2 Product Portfolio
- 27.10.3 Demographic Reach and Achievements
- 27.10.4 Company News and Development
- 27.10.5 Certifications
- 28 Ulcerative Colitis Market - Distribution Model (Additional Insight)
- 28.1 Overview
- 28.2 Potential Distributors
- 28.3 Key Parameters for Distribution Partner Assessment
- 29 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
